A phase II study of perifosine in patients with relapsed/refractory Waldenstrom's macroglobulinaemia.
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Perifosine (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 17 Apr 2011 Planned End Date changed from 1 Sep 2011 to 1 Oct 2011, according to ClinicalTrials.gov record.
- 23 Feb 2010 Planned end date changed from 1 Mar 2009 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 29 Jan 2010 Positive top-line data reported in a Keryx Biopharmaceuticals media release, with results to be published in the February 1, 2010 issue of Clinical Cancer Research.